Analyst Research

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Anika Therapeutics Inc receives FDA approval for MONOVISC


Tuesday, 25 Feb 2014 03:59pm EST 

Anika Therapeutics Inc:Receives marketing approval for MONOVISC from the U.S. Food and Drug Administration (FDA).Says MONOVISC is the first FDA approved single injection product with HA from a non-animal source.Says MONOVISC will be marketed in the U.S. by DePuy Synthes, Mitek Sports Medicine (Mitek).Says under the license agreement with Mitek, Anika will receive a milestone payment of $5 mln upon first commercial sale of MONOVISC in the market. 

Company Quote

35.56
0.15 +0.42%
1:31pm EDT